Insulin-like growth factor physiology and cancer risk

European Journal of Cancer

Volumn 36, Issue 10, 2000, Pages 1224-1228

  Pollak, M ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Colon cancer; IGF I; IGFBP 3; Lung cancer; Prevention; Prostate cancer; Risk

Indexed keywords

ANTIANDROGEN; ANTIESTROGEN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOSTATIN DERIVATIVE; VITAMIN D DERIVATIVE;

BREAST CANCER; CANCER; CANCER PREVENTION; CANCER RISK; CARCINOMA; COLON CANCER; CONFERENCE PAPER; GENE MUTATION; GERM LINE; HUMAN; HYPOTHESIS; LABORATORY TEST; LUNG CANCER; NONHUMAN; PHYSIOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER;

BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0034082039     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00102-7     Document Type: Conference Paper

References (52)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endo Rev 1995, 16, 3-34.
2. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factorbinding proteins in serum and other biological fluids: regulation and functions. Endo Rev 1997, 18, 801-831.
3. Harrela M, Koinstinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996, 98, 2612-2615.
4. Kao PC, Matheny APJ, Lang CA. Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol & Metab 1994, 78, 310-312.
5. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endo Rev 1994, 15, 80-101.
6. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351, 1393-1396.
7. Peyrat JP, Bonneterre J, Hecquet B, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993, 29A, 492-97.
8. Chan JM, Stampfer MK, Giovannucci E, et al. Plasma insulinlike growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279, 563-566.
9. Ma J, Pollak M, Giovannucci E, et al. Prospective study of plasma levels of insulin-like growth factor I, insulin-like growth factor binding protein-3 and colorectal cancer risk among men. J Nail Cancer Inst 1999, 91, 620-625.
10. Wolk A, Mantzoros CS, Andersson S-O, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998, 90, 911-915.
11. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulinlike growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998, 9, 570-573.
12. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a casecontrol analysis. J Natl Cancer Inst 1999, 91, 151-156.
13. Manousos O, Souglakos J, Bosetti C, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999, 83, 15-17.
14. Dunn SE, Kari FW, French J, et al. Dietary restriction reduces IGF-I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53 deficient mice. Cancer Res 1997, 57, 4667-4672.
15. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Koumantaki Y, Mantzoros CS. Dietary fat and carbohydrates are independantly associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J Clin Oncol 1999, 17, 3291-3298.
16. Maison P, Baikau B, Simon D, Chanson P, Rosselin G, Eschwege E. Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. Br Med J 1998, 316, 1132-1133.
17. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science 1990, 249, 1007-1011.
18. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990, 50, 7415-7421.
19. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999, 96, 7324-7329.
20. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Medicine 1997, 3, 1141-1144.
21. Pollak M, Beamer W, Zhang J-C. Insulin-like growth factors and prostate cancer. Cancer and Metastases Rev 1999, 17, 383-390.
22. Wu X, Yu H, Amos CI, Hong WK, Spitz MR. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst 2000, 92, 737-743.
23. Byrne C, Hankinson S, Pollak M, et al. A cross sectional study of mammographie density and plasma hormones. Cancer Res 2000, in press.
24. Wilson RG, Smith AN, Bird CC. Immunohistochemical detection of abnormal cell proliferation in colonie mucosa of subjects with polyps. J Clin Palhol 1990, 43, 744-747.
25. Terpstra OT, van Blankenstein M, Dees J, Eilers GA. Abnormal pattern of cell proliferation in the entire colonie mucosa of patients with colon adenoma or cancer. Gastroenterology 1987, 92, 704-708.
26. Ponz de Leon M, Roncucci L, Di Donato P, et al. Pattern of epithelial cell proliferation in colorectal mucosa of normal subjects and of patients with adenomatous polyps or cancer of the large bowel. Cancer Res 1988, 48, 4121-4126.
27. Scalmati A, Roncucci L, Ghidini G, Biasco G, Ponz D, Leon M. Epithelial cell kinetics in the remaining colorectal mucosa after surgery for cancer of the large bowel. Cancer Res 1990, 50, 7937-7941.
28. Risio M, Lipkin M, Candelaresi G, Bertone A, Coverlizza S, Rossini FP. Correlations between rectal mucosa cell proliferation and the clinical and pathological features of nonfamilial neoplasia of the large intestine. Cancer Res 1991, 51, 1917-1921.
29. Cats A, Dullaart RP, Kleinbeuker JH, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 1996, 56, 523-526.
30. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science 1997, 276, 1268-1272.
31. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997, 272, 12181-12188.
32. Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rPl) is a potential tumor suppressor protein for prostate cancer. Cancer Res 1999, 59, 2370-2375.
33. Huynh HT, Yang XF, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996, 271, 1016-1021.
34. Huynh HT, Tetenes E, Wallace L, Pollak M. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res 1993, 53, 1727-1730.
35. Nickerson T, Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology 1999, 54, 1120-1125.
36. Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. Endocrinol 1998, 139, 807-810.
37. Nickerson T, Miyake H, Cleave ME, Pollak M. Castrationinduced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding IGFbinding proteins. Cancer Res 1999, 59, 3392-3395.
38. Nickerson T, Zhang J-C, Pollak M. Regression of DMBAinduced breast carcinoma following ovariectomy is associated with increased expression of genes encoding insulin-like growth factor binding proteins. In t J Oncol 1999, 14, 987-990.
39. 3 and its analog EB1089. Int J Oncol 1998, 13, 137-143.
40. Rozen F, Yang X, Huynh HT, Pollak M. Antiproliferative action of vitamin-D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 1997, 89, 652-656.
41. Dunn SE, Ehrlich M, Sharp NJ, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998, 58, 3353-3361.
42. Baserga R. Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol 1996, 14, 150-152.
43. Yang XF, Beamer W, Huynh HT, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation. Cancer Res 1996, 56, 1509-1511.
44. Pollak M, Schally AV. Mechanism of antineoplastic action of somatostatin analogues. Proc Soc Exp Biol Med 1998, 217, 143-152.
45. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res 1994, 54, 6334-6337.
46. Ingle J, Suman VJ, Kardinal CG, et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast cancer. Cancer 1999, 85, 1284-1292.
47. Pollak M, Costantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990, 82, 1693-1697.
48. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90, 1371-1388.
49. Veronesi U, De PG, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999, 91, 1847-1856.
50. Torrisi R, Parodi S, Fontana V, et al. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int J Cancer 1998, 76, 787-790.
51. Gobbi H, Dupont WD, Simpson JF, et al. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999, 15, 2096-2101.
52. Huynh H, Beamer W, Pollak M, Chan TW. Modulation of transforming growth factor betal gene expression in the mammary gland by insulin-like growth factor I and octreotide. Int J Oncol 2000, 16, 277-281.